Ocugen's India Partnered COVID-19 Vaccine Gets WHO Approval: Report

WHO's Technical Advisory Group has recommended the Emergency Use Listing status for Bharat Biotech's COVID-19, Covaxin.
Read Next: Ocugen Reverses Course From Monday's Massive Surge As COVID-19 Vaccine Partner Faces WHO Setback.
Ocugen Inc OCGN is the U.S. partner for the India-made vaccine.
The World Health Organization's panel had last week sought additional clarifications from the firm.
The Technical Advisory Group had met on October 26 and sought additional details from Bharat Biotech.
Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.
Related Link: Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report.
WHO's approval will open travel channels to several countries that are yet to include Covaxin in their approved list of vaccines.
Additionally, Covaxin has been granted an extension of shelf life for up to 12 months from the date of manufacture by India's drug regulator.
Covaxin initially had a shelf life of six months.
Price Action: OCGN shares are down 4.47% at $14.98 during the market session on the last check Wednesday.

Momentum10.05

Growth-

Quality-

Value8.09

Short

Medium

Long